Table 3.

Performance of serum adiponectin in the differential diagnosis of NAFL vs. NASH in patients homozygous for the wild-type allele CC in the PNPLA3 rs738409 polymorphism.

	Cutoff	AUROC (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Accuracy (95% CI)	PPV (95% CI)	NPV (95% CI)	TP	TN	FP	FN
Adiponectin	<7.32 μg/ml	0.63* (0.52–0.73)	0.85 (0.72–0.94)	0.29 (0.18–0.42)	0.54 (0.44–0.64)	0.49 (0.44–0.54)	0.71 (0.52–0.84)	40	17	42	7
AST/ALT	<0.96	0.65** (0.55–0.76)	0.89 (0.77–0.96)	0.49 (0.36–0.63)	0.67 (0.75–0.76)	0.59 (0.52–0.66)	0.85 (0.70–0.93)	42	28	29	5
MRI	>0.15	0.90**** (0.69–0.91)	0.85 (0.68–0.95)	0.68 (0.50–0.83)	0.76 (0.64–0.86)	0.72 (0.61–0.81)	0.82 (0.67–0.91)	28	11	5	23
Hepatic TG content evaluated by Folch method	>42.85 mg/g	0.75*** (0.63–0.87)	0.83 (0.67–0.94)	0.59 (0.42–0.74)	0.70 (0.59–0.80)	0.64 (0.54–0.72)	0.80 (0.65–0.90)	30	24	17	6

Applied in validation cohort. Adiponectin; n = 106; AST/ALT, n = 104; MRI, n = 67; hepatic TG content evaluated by Folch method, n = 77. NASH is considered positive if the levels of each parameter are superior or inferior to the cutoff value as indicated.

AST/ALT, aspartate aminotransferase to alanine aminotransferase ratio; CI, confidence interval; FN, false negative; FP, false positive; MRI, magnetic resonance imaging; NAFL, nonalcoholic fatty liver; NASH, nonalcoholic steatohepatitis; NPV, negative predictive value; PPV, positive predictive value; TN, true negative; TP, true positive.

^*p < 0.05;

^**p < 0.01;

^***p < 0.001;

^****p < 0.0001.